Edwards Lifesciences Corporation [NYSE: EW] slipped around -0.93 points on Friday, while shares priced at $84.31 at the close of the session, down -1.09%. The company report on February 1, 2021 that Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years.
Edwards Lifesciences (NYSE: EW) announced new data from the COMMENCE clinical trial that demonstrate Edwards’ bioprosthetic surgical aortic valve with the company’s novel RESILIA tissue platform show favorable safety and hemodynamic performance through a median of five years follow-up. The data were presented at the 57th annual meeting of the Society of Thoracic Surgeons.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
“There continues to be a significant focus placed on tissue valve durability given the increase in life expectancy and lifestyle implications for more active patients who historically would receive mechanical valves,” said Joseph E. Bavaria, M.D., lead enroller and site principal investigator for the COMMENCE study and the Brooke Roberts-William M. Measey professor of surgery and vice chief of the division of cardiovascular surgery, University of Pennsylvania. “The latest data from the COMMENCE study are encouraging and speak to the promise of RESILIA tissue as a significant advancement in technology for patients with valve disease.”.
Edwards Lifesciences Corporation stock is now -7.59% down from its year-to-date (YTD) trading value. EW Stock saw the intraday high of $85.815 and lowest of $83.99 per share. The company’s 52-week high price is 92.08, which means current price is +3.30% above from all time high which was touched on 01/04/21.
Compared to the average trading volume of 2.42M shares, EW reached a trading volume of 4797491 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Edwards Lifesciences Corporation [EW]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $94.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Edwards Lifesciences Corporation shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 16, 2020. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price from $89 to $94. The new note on the price target was released on December 11, 2020, representing the official price target for Edwards Lifesciences Corporation stock. On April 28, 2020, analysts decreased their price target for EW shares from 250 to 230.
The Average True Range (ATR) for Edwards Lifesciences Corporation is set at 1.99, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 12.14. The Price to Book ratio for the last quarter was 11.49, with the Price to Cash per share for the same quarter was set at 2.22. Price to Free Cash Flow for EW in the course of the last twelve months was 82.24 with Quick ratio for the last quarter at 2.60.
How has EW stock performed recently?
Edwards Lifesciences Corporation [EW] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.27. With this latest performance, EW shares dropped by -4.30% in over the last four-week period, additionally plugging by 7.03% over the last 6 months – not to mention a rise of 8.13% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 43.39, with the RSI for the last a single of trading hit 39.87, and the three-weeks RSI is set at 45.75 for Edwards Lifesciences Corporation [EW]. The present Moving Average for the last 50 days of trading for this stock 86.70, while it was recorded at 85.85 for the last single week of trading, and 79.76 for the last 200 days.
Edwards Lifesciences Corporation [EW]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Edwards Lifesciences Corporation [EW] shares currently have an operating margin of +29.55 and a Gross Margin at +74.94. Edwards Lifesciences Corporation’s Net Margin is presently recorded at +18.77.
Return on Total Capital for EW is now 25.67, given the latest momentum, and Return on Invested Capital for the company is 16.40. Return on Equity for this stock inclined to 18.88, with Return on Assets sitting at 12.00. When it comes to the capital structure of this company, Edwards Lifesciences Corporation [EW] has a Total Debt to Total Equity ratio set at 15.19. Additionally, EW Total Debt to Total Capital is recorded at 13.19, with Total Debt to Total Assets ending up at 9.60. Long-Term Debt to Equity for the company is recorded at 14.60, with the Long-Term Debt to Total Capital now at 12.67.
Reflecting on the efficiency of the workforce at the company, Edwards Lifesciences Corporation [EW] managed to generate an average of $55,262 per employee. Receivables Turnover for the company is 7.30 with a Total Asset Turnover recorded at a value of 0.64.Edwards Lifesciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 3.50.
Earnings analysis for Edwards Lifesciences Corporation [EW]
With the latest financial reports released by the company, Edwards Lifesciences Corporation posted 0.5/share EPS, while the average EPS was predicted by analysts to be reported at 0.44/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corporation go to 13.00%.
Insider trade positions for Edwards Lifesciences Corporation [EW]
There are presently around $42,835 million, or 86.30% of EW stock, in the hands of institutional investors. The top three institutional holders of EW stocks are: BLACKROCK INC. with ownership of 58,596,560, which is approximately -0.747% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 48,347,685 shares of the stock with an approximate value of $4.08 billion in EW stocks shares; and STATE STREET CORP, currently with $2.18 billion in EW stock with ownership of nearly -3.339% of the company’s market capitalization.
Positions in Edwards Lifesciences Corporation stocks held by institutional investors increased at the end of January and at the time of the January reporting period, where 551 institutional holders increased their position in Edwards Lifesciences Corporation [NYSE:EW] by around 24,625,141 shares. Additionally, 474 investors decreased positions by around 24,737,385 shares, while 188 investors held positions by with 458,701,122 shares. The mentioned changes placed institutional holdings at 508,063,648 shares, according to the latest SEC report filing. EW stock had 149 new institutional investments in for a total of 4,263,010 shares, while 78 institutional investors sold positions of 1,192,995 shares during the same period.